Dosing. Except as agreed to by the FDA or an equivalent foreign regulatory agency or body, Seelos shall not exceed the maximum allowable dosing levels of Captisol specified in CyDex’s then-current clinical dosing matrix (which shall be provided by CyDex to Seelos from time to time) without the written consent of CyDex, which consent shall not be unreasonably withheld or delayed.
Appears in 2 contracts
Sources: License Agreement (Apricus Biosciences, Inc.), License Agreement (Apricus Biosciences, Inc.)